NICE TAs

romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura in adults

Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.

This guidance replaces NICE technology appraisal guidance on:

• etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and 
• adalimumab for the treatment of psoriatic arthritis (TA125).

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.

Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.

Evidence-based recommendations on collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture in adults.

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

Evidence-based recommendations on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.